Here’s whether Aclaris Therapeutics, Inc. (ACRS) is worth buying in 2026 —
based on weekly-updated price trend, RSI momentum, and return vs.
the S&P 500. Our current read: Bullish.
🟢
Bullish
Positives: trading above the 200-day MA (long-term uptrend intact); above the 50-day MA (medium-term momentum positive); 50-day MA is rising (+6.40% over 10 days); strong 1-year return of +266.3%; 3-month momentum positive (+41.8%). Concerns: declining volume on rally — weak conviction (0.76x 30d avg). Currently 1.6% off its 52-week high. Score: +5/7.
ACRS is in a confirmed uptrend, trading above both its 50-day ($5.44) and 200-day ($4.02) moving averages. An RSI of 68.8 sits in the neutral zone — momentum is neither stretched nor exhausted. The 1-year return of +266.3% compares to +20.5% for SPY (beat the market by 245.8%).
$10,000 invested 1 year ago→ $36,629 today
vs. S&P 500 (SPY) — same period beat market by 245.8%